PMP22 and hereditary neuropathy with liability to pressure palsies: Ideally, CMT1A therapies should reduce overexpressed PMP22, while avoiding excessive knockdown that could lead to the milder phenotype of hereditary neuropathy with pressure palsies (HNPP).